Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H R Hendriks

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1994
Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up studyS P Langdon, H R Hendriks, B J Braakhuis, et al.
Anticancer Research|May 27, 2004
Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivoA Varvaresou, K Iakovou, E Gikas, et al.
Biochemical Pharmacology|March 24, 2004
Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell linesA M Bergman, C M Kuiper, D A Voorn, et al.
Nucleosides & Nucleotides|August 5, 1999
Cell specific cytotoxicity and structure-activity relationship of lipophilic 1-B-D-arabinofuranosylcytosine (ara-C) derivativesG J Peters, D A Voorn, C M Kuiper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1992
Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agentH R Hendriks, J Plowman, D P Berger, et al.
Nucleosides, Nucleotides & Nucleic Acids|December 2, 2004
Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenograftsA M Bergman, C M Kuiper, P Noordhuis, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical modelsH R Hendriks, P E Pizao, D P Berger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industryR Bartsch, S Frings, M Marty, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1994
Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up studyS P Langdon, H R Hendriks, B J Braakhuis, et al.
Anticancer Research|May 27, 2004
Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivoA Varvaresou, K Iakovou, E Gikas, et al.
Biochemical Pharmacology|March 24, 2004
Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell linesA M Bergman, C M Kuiper, D A Voorn, et al.
Nucleosides & Nucleotides|August 5, 1999
Cell specific cytotoxicity and structure-activity relationship of lipophilic 1-B-D-arabinofuranosylcytosine (ara-C) derivativesG J Peters, D A Voorn, C M Kuiper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1992
Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agentH R Hendriks, J Plowman, D P Berger, et al.
Nucleosides, Nucleotides & Nucleic Acids|December 2, 2004
Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenograftsA M Bergman, C M Kuiper, P Noordhuis, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical modelsH R Hendriks, P E Pizao, D P Berger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industryR Bartsch, S Frings, M Marty, et al.
Pageof 4